PHARMACOKINETICS AND SAFETY OF TENOFOVIR ALAFENAMIDE IN SUBJECTS WITH SEVERE HEPATIC IMPAIRMENT

被引：5
|
作者：
Custodio, J. M. [1 ]
Ma, G. [1 ]
Cuvin, J. [1 ]
Ting, L. [1 ]
Flaherty, J. [1 ]
Zack, J. Z. [1 ]
机构：
[1] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
JOURNAL OF HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
10.1016/S0168-8278(16)01095-3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI-127
引用
收藏
页码：S594 / S595
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment
    Custodio, Joseph M.
    Fordyce, Marshall
    Garner, William
    Vimal, Mona
    Ling, Kah Hiing J.
    Kearney, Brian P.
    Ramanathan, Srinivasan
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (09) : 5135 - 5140
  • [2] The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (08): : 944 - 952
  • [3] Safety of tenofovir alafenamide in renal impairment
    Pozniak, A.
    Arribas, J.
    Gupta, S.
    Post, F.
    Avihingsanon, A.
    Crofoot, G.
    Lichtenstein, K.
    Ramgopa, M.
    Chetchotisakd, P.
    Benn, P.
    Fordyce, M. W.
    [J]. HIV MEDICINE, 2015, 16 : 33 - 33
  • [4] The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT.
    Xin, Y.
    Collins, H.
    Cheng, F.
    Kwan, E.
    Ramanathan, S.
    Silverman, J. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S88 - S88
  • [6] Pharmacokinetics of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects
    Yamada, Hiroyuki
    Yonemura, Takuma
    Nemoto, Takanori
    Ninomiya, Noriko
    Irie, Shin
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (04): : 511 - 520
  • [7] Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment
    Jamieson, Brian D.
    Ciric, Sabrina
    Fernandes, Prabhavathi
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 4379 - 4386
  • [8] Pharmacokinetics and Safety of Teneligliptin in Subjects With Hepatic Impairment
    Halabi, Atef
    Maatouk, Haidar
    Siegler, Karl Ernst
    Faisst, Nadja
    Hinrichsen, Holger
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (04): : 290 - 296
  • [9] The Pharmacokinetics and Safety Of Idelalisib In Subjects With Moderate Or Severe Hepatic Impairment<bold> </bold>
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    [J]. BLOOD, 2013, 122 (21)
  • [10] PHARMACOKINETICS AND SAFETY OF NITAZOXANIDE IN SUBJECTS WITH HEPATIC IMPAIRMENT
    Harisseh, Rania
    Finnegan, Beth
    Thomas, Stephane
    Legry, Vanessa
    Hum, Dean
    Marbury, Thomas C.
    Perry, Robert G.
    Wyatt, David J.
    Addy, Carol
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S1391 - S1391
12345